Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors
September 29, 2010
In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:
Medicare product coverage strategy
Proper planning for product pricing
Preparing comparative effectiveness data
Working with payer expectations
Data that should be in place for partnering or acquisition deals
Panelists:
Judith A. Waltz, Partner, Foley & Lardner LLP
Anita Chawla, Ph.D., Vice President, Analysis Group
Related Insights
August 12, 2025
Foley Viewpoints
The Executive Order Guaranteeing Fair Banking for All Americans and Its Implications for State Regulation of Insurance Trade Practices Related to Political Opinions
On August 7, 2025, the White House issued an Executive Order titled “Guaranteeing Fair Banking for All Americans,” which is intended to…
August 12, 2025
Health Care Law Today
Health Care Marketing Enforcement: FTC Targets Telehealth Company for Deceptive Weight Loss Marketing Claims
On July 14, 2025, the operators of telemedicine company Southern Health Solutions, Inc., doing business as Next Medical and NextMed,…
August 12, 2025
Energy Current
Inside DOE’s 10-Reactor Fleet Program: A Practical Guide
The U.S. Department of Energy (DOE) unveiled its Reactor Pilot Program – also known as the 10 Reactor Fleet Program – in reaction to one…